

## Review Articles

# Bacteriophage applications in aquaculture

Ifakat T. Çağatay<sup>1a</sup><sup>1</sup> Akdeniz University, Faculty of Fisheries, Department of Basic Sciences, Campus, 07050 Antalya, Türkiye

Keywords: aquaculture, bacterial pathogens, bacteriophage, fish diseases

<https://doi.org/10.46989/001c.78119>

---

## Israeli Journal of Aquaculture - Bamidgeh

Vol. 75, Issue 2, 2023

---

Aquaculture has grown tremendously due to the big demand for its products. However, diseases affecting aquaculture and economic losses are worldwide problems and it needs low cost, sustainable, highly efficient, specific and eco-friendly therapeutants. Due to the rising up antibiotic resistant-microorganism, bacteriophage therapy has reinvigorated to replace antibiotics in agriculture, medicine, food safety and the environment. Likewise, it also holds great promise to avoid, control and treat bacteria in aquaculture to decrease the mortality level of different aquatic animal diseases. The isolation and characterization of new phages and phage application therapy to eliminate bacterial fish and shellfish pathogens such as *Vibrio*, *Aeromonas*, *Pseudomonas*, *Lactococcus*, *Yersinia*, *Flavobacterium*, and *Streptococcus* was gradually reported in aquaculture literature. The present review summarizes large-scale reports *in vitro* or *in vivo* use of aquaphage studies and applications in fish diseases from the 1980s to 2022 and future directions.

### INTRODUCTION

Aquaculture is a rapidly growing industry worldwide, from which people derive about 50% of their animal protein requirements.<sup>1</sup> As the Food and Agriculture Organization reported in 2020, aquaculture production in 2030, which provides about 1/3 of the world's aquaculture resources, is estimated to rise to 53%.<sup>2</sup> In addition to fish, species such as carp, tilapia, and trout and aquatic organisms such as oysters, clams, and shrimps are grown in aquaculture in fresh and marine waters.<sup>3</sup>

However, aquaculture suffers from heavy financial losses every year globally because of viral, fungal, parasitic, and bacterial disease outbreaks at any stage of the breeding process.<sup>4-7</sup> The same bacterial pathogens detected disease agents in aquatic organisms: Gram-negative *Aeromonas salmonicida*, *A. hydrophila*, *Pseudomonas plecoglossicida*, *Edwardsiella tarda*, *E. piscicida*, *E. ictaluri*, *Vibrio* spp. (*V. harveyi*, *V. parahaemolyticus*, *V. anguillarum*, *V. splendidus*, *V. alginolyticus*, *V. coralliilyticus*), *Flavobacterium columnare*, *F. psychrophilum*, *Yersinia ruckeri* and Gram-positive *Lactococcus garvieae*, *Renibacterium salmoninarum*, *Streptococcus iniae*, *Mycobacterium* species.<sup>8,9</sup> These bacterial pathogens that are easily transmitted through water in case of external stressors, including intensive stock densities, inadequate nutrition, build-up of toxic chemicals, poor water quality, and low oxygenation, can therefore infect many aquatic organisms.

Various strategies, including probiotics, prebiotics, immunostimulants, and vaccination, have increased fish defense and prevented bacterial diseases.<sup>10,11</sup> However, vaccine administration methods and routes vary depending on species, quantity, size of organisms, pathogens, temperature, and environment.<sup>12,13</sup> Therefore, vaccination becomes a tedious job for large-scale aquaculture systems. Also, vaccines may not be as effective against larvae and invertebrates without a robust immune system.<sup>14</sup> Of the biocides, malachite green is used in the treatment of protozoal and fungal infections, while formaldehyde and formalin solutions are prophylactic disinfectants for eggs and larval development.

The use of amoxicillin, oxytetracycline, sulfonamides, tetracyclines, nitrofurans, fluoroquinolones, and florfenicol among antibiotics as a therapeutic agent is also the most preferred method to inhibit the growth of bacteria and stop heavy mortalities during outbreaks of infectious bacterial diseases in aquaculture and fisheries.<sup>8,13,15</sup> Although they are rapid, effective and commonly used for bacterial infection of aquaculture and agriculture, antibiotics generally target both pathogenic and non-pathogenic microflora of the environment. In addition, their long-term and heavy use caused a number of unfavourable impacts such as accumulation and toxicity in organisms, occurrence of antibiotic-resistant bacterial strains and suppression of the immune response of the host, thus increasing the ineffectiveness of antibiotic treatments.<sup>9,11,13,16</sup> The above disadvantages of antibiotics have prompted the development of species-specific, eco-friendly and less expensive way to

---

a \* Corresponding author e-mail: tulaycagatay@gmail.com

prevent bacterial infectious diseases in sustainable aquaculture.<sup>3,7</sup> In search of alternative tool or a possible solution, the use of bacteriophages seems to be very promising and appropriate strategy as approached “post-antibiotic era” as the World Health Organisation (WHO) announced in different diseases of animals.<sup>17-22</sup>

This review mainly focuses on and summarizes extensive research literature in the last 40 years and future directions, with many different bacteriophages and its applications and outcomes as alternative ways, due to overuse of antibiotics, to prevent, control and treat diseases in aquatic organisms (such as crustaceans, molluscs and fish) and their environment.

## PHAGE MORPHOLOGY

The bacteriophages, also known as phages (meant to imply “eat” or “devour” in Greek), are very small bacterial viruses that can range in size from 20 to 200 nm, are host-specific, and can only infect and kill targeted bacteria, without harming the surrounding microbiota and animal or plant cells.<sup>23-25</sup> Diverse phages can be found in all environments that are abundant in nature, such as river and seawater, sediments, soil, sewage, and food products, and were also readily detected in human and animal feces/urine.<sup>26-28</sup>

The taxonomy and three-dimensional structure of typical phage morphology is well defined. It is classified according to their general morphology, the presence of outer envelope and lipid structures, and the type of genome that is in the form of ssRNA, dsRNA, ssDNA and dsDNA.<sup>17,29-31</sup> According to this approach, the International Committee for Taxonomy of Viruses (ICTV) identified 14 distinct and well-characterized phage families: Myoviridae, Podoviridae, Siphoviridae, Microviridae, Inoviridae, Herelleviridae, and Ackermannviridae, as shown in [Table 1](#). [Table 1](#) has been prepared according to information from Acherman<sup>32</sup>,<sup>33</sup> and Sharp et al.<sup>34</sup>

The phage genome is enclosed in a protein capsid head (e.g., filamentous, helical, icosahedral, pleomorphic, and polyhedral), a tail with spiral sheath and tail fibers and surface receptors responsible for recognizing specific host bacterial molecules and attaches themselves to the cell's surface.<sup>35,36</sup> These phages, which cannot perform their molecular replication under normal conditions, now use the host mechanism to reproduce themselves after their genome is injected into the bacterial host. They take over the bacterial biosynthesis control mechanism and command the bacterial host to produce different viral proteins and release progeny and phages that can continue to infect other hosts.

## PHAGE LIFE CYCLE















Phages can multiply and propagate by infecting bacteria in 2 paths: 1) lytic life cycle (virulent) and 2) lysogenic life cycle (temperate-dormant). The first phage cycle, which lasts between 20 minutes and 2 hours, begins when phages attach to the host, integrate their genetic material, and continue to multiply to produce viral progeny. The virulent

phages will control the host's protein. This cycle results in the secretion of lysins and holins enzymes by phages, lysis of the host bacterial cell membrane, and releasing the newly formed progeny virions into the environment. Afterward, the new progenies infect different host bacteria. The lysogenic (temperate) phages, in contrast, attach their genome to the host's and remain in a dormant and stable stage for a long time until environmental conditions are favorable for the rapid growth of new prophages.<sup>36-42</sup> Therefore, lytic phages that proliferate exponentially and damage the pathogenic host in any case of antibiotic resistance status are more amenable to developing therapeutic intent.

## PHAGE HISTORY AND THEIR POTENTIAL APPLICATIONS

Phages therapy first came onto the scientific domain about a hundred years ago after finding by Twort<sup>43</sup> and d'Herelle,<sup>44</sup> respectively.<sup>23,40,45-48</sup> Phage has been used successfully to treat severe hemorrhagic Shigella dysentery among French troops patients and against cholera by Vibrio cholera in India.<sup>30,31,49,50</sup> Bruynoghe and Maisin<sup>51</sup> reported phage therapy treatment of staphylococcal skin disease. The first commercial phage in history was the anticholine phage, successfully used to control the epidemic that threatened the southeastern regions of the Soviet Union (SSCB) and then Georgia in 1931.<sup>52</sup> In the 1930s and 1940s, the phage therapy application against mixed bacteria caused by *Clostridium perfringens*, *Staphylococcus*, *Streptococcus*, *Escherichia coli* and *Proteus* species were tested in Poland, Belarus, Georgia, Russia, Ukraine, and Azerbaijan.<sup>23,53</sup> Concurrent with the advent of commercial antibiotics in the 1940s, there was a huge decline in using phages as therapeutic agents in Western countries and the United States. However, in the period from the 1950s to late 1970s, the SSCB and in East Europe continued using the phage treatment against *S. typhi* and *S. paratyphi* and phage for prophylaxis in the fast spread of infections occurred such as military and schools.<sup>54,55</sup> In the 1980s, Smith et al.<sup>56</sup> showed that *E. coli* diarrhea in calves could be treated with phage, and this successful result then prompted the West to explore the possibility that phages could be used in human infections as well.

Because of the occurrence of multi-antibiotic-resistant bacteria, phages have been reappraised in the last two decades and are at the forefront again as therapeutic/prophylactic agents against human infectious diseases,<sup>18,42,57-60</sup> aquaculture,<sup>15,61-63</sup> agriculture, animal and plant pathogens,<sup>40,64,65</sup> food<sup>23,36,66</sup>, wastewater<sup>31,67,68</sup> and other subjects like biofilm removers<sup>69,70</sup> and biosensor.<sup>71</sup> Multiple studies on using phages in animal agriculture have explored *Salmonella*, *E. coli*, *Clostridium*, and *Campylobacter* for the pig, chicken, cattle, and sheep industries.<sup>22,72,73</sup> [Figure 1](#) summarizes phage applications in different areas.

Family	Morphology	Nucleic acid	Characteristics
<i>Myoviridae</i>		Linear dsDNA	contractile tail, non-enveloped
<i>Siphoviridae</i>		Linear dsDNA	long noncontractile tail, non-enveloped
<i>Podoviridae</i>		Linear dsDNA	short noncontractile tail, non-enveloped
<i>Tectiviridae</i>		Linear dsDNA	isometric, non-enveloped
<i>Corticoviridae</i>		Circular dsDNA	isometric, non-enveloped
<i>Lipothrixviridae</i>		Linear dsDNA	rod shaped, enveloped
<i>Plasmaviridae</i>		Circular dsDNA	pleomorphic, enveloped
<i>Rudiviridae</i>		Linear dsDNA	rod shaped, enveloped
<i>Fuselloviridae</i>		Circular dsDNA	lemon shaped, non-enveloped
<i>Inoviridae</i>		Circular ssDNA	filamentous, non-enveloped
<i>Inoviridae</i>		Circular ssDNA	filamentous, non-enveloped
<i>Microviridae</i>		Circular ssDNA	Isometric, non-enveloped
<i>Leviviridae</i>		Linear ssRNA	Isometric, non-enveloped
<i>Cystoviridae</i>		Segmented dsRNA	spherical, enveloped

**Table 1. Morphology and genome characteristics of the fourteen phage families**

## PHAGE APPLICATIONS IN FISH DISEASES AND AQUACULTURE

The aquaculture and farmed fish industry have high mortality rates and considerable economic losses because of certain microbial infectious diseases. Widespread bacterial fish diseases are aeromoniasis, hemorrhagic septicemia, furunculosis, vibriosis, edwardsiellosis, mycobacteriosis, ulcer disease, columnaris, lactococcosis, enteric red mouth disease, fry syndrome, and cold-water disease, respectively.<sup>8</sup> Phages were used to control and prevent bacterial infections caused by antibiotic-resistant bacteria at the laboratory level or in small-scale trials for field applications in aquaculture.


The essential step in aquatic phage therapy is identifying the fish disease agent and then detecting and isolating the phage that can effectively infect the host bacteria. The phage and bacteria interactions are essential to inactivate possible aquatic pathogens. Phages can interact with hosts bacteria to the lytic cycles, replicate their genome, and produce new phages that let out bacterial cell lysis into ponds, lakes, seas, rivers, and sewage, infecting new bacterial cells. New phages are exponentially replicated, and the num-

ber of bacteria decreases and disappears. [Figure 2](#) is an overview of the steps of phage application in aquaculture.

Our literature review screened numerous google scholar publications from 1997 to 2022 when typed in “Bacteriophages, aquaculture, and twelve fish pathogens” as the keywords ([Figure 3](#)). And as shown in the bar graph, the number of research studies on phage therapy applications in aquaculture has gradually increased worldwide for twelve bacterial agents.

There is a selection of studies on the genetic/morphologic identification, characterization of phages, and the effectiveness of different phages for biocontrol and treatment in eggs, larvae, juveniles and adult fish and shrimp, other aquatic organisms, and aquaculture food products.

In addition, numerous reviews have reported that the most studied phage families are Myoviridae, Podoviridae, and Siphoviridae as virulence and control tool against a wide variety of pathogens, *A. salmonicida*, *A. hydrophila*, *E. tarda*, *Y. ruckeri*, *V. harveyi*, *V. parahaemolyticus*, *V. anguillarum*, *V. alginolyticus*, *F. columnare*, *F. psychrophilum*, *L. garviae* and *S. iniae*, in vitro or in vivo.<sup>9,11,15,21,30,41,74-79</sup>



**Figure 1. Illustration of phage applications in human, aquaculture, food, agriculture, and environment**

A list of reported phage applications and outcomes against the most significant bacterial pathogens in aquaculture from 1981 to 2022 is shown in [Table 2](#).

The result of summarized studies in [Table 2](#) using phages specific to 12 fish diseases agents as direct or suspensions of single or cocktail, oral administration, injections, or as aquafeed<sup>174-176</sup> recommend that phages could be beneficial to prevent and treat bacterial infections of aquatic animals. Even though different methods are used, the literature indicates that the most prophylactic impact appears when administered intraperitoneally (Americo et al., 2020). Additionally, in recent years, the other practical way was using commercial phages developed and used against some pathogens of aquaculture.<sup>41,177</sup> For example, Intralytix and Phage Biotech Ltd have developed phages to destroy *Vibrio* spp. in oyster and shrimp aquaculture,<sup>178,179</sup> Phage named BAFADOR® registered by Proteon pharmaceutical against *Aeromonas* spp. and *Pseudomonas* spp.<sup>180</sup>,<sup>181</sup> ACD Pharma has developed phage solutions against *Y. ruckeri*.<sup>182</sup> Fixed Phage Ltd. has developed aquafeed-phage pellets.<sup>183</sup> Mangalore Biotech Laboratory has also developed LUMI-NIL MBL to control pathogens in shrimp.<sup>184</sup>

The first research on phage therapy used in aquaculture was notified by Wu and co-workers in 1981 as the pathogenicity loss of *A. hydrophila* to loach (*M. anguillicaudatus*), in which Ah1 phage infected the pathogen.<sup>88</sup> Numerous studies have declared the accomplished use of more than 35 *A. hydrophila* phages aiming to control motile *Aeromonas* and septicemia from 1981 to 2022 ([Table 2](#)).<sup>40,90,92,93,96-105,175,185,186</sup>

Around 22 phages with treatment activity against *A. salmonicida* (caused furunculosis) have been identified and characterized from farm fish ([Table 2](#)).<sup>26,80-87</sup>

Four phages named PLgY-16, PLgY-30, and PLgW-1 were used to treat *L. garvieae* infection in yellowtail (*S. quinqueradiata*)<sup>150,151(p1998)</sup> and *P. plecoglossicida* infection in ayu (*P. altivelis*)<sup>61,152</sup> in the 1990s.

From 2000 to 2022, more lysogenic phages named PLgT-1, PLgY-30, PLG-II, and WWP-1 were involved in *L. garvieae* infection colonizing marine fish, *S. quinqueradiata*, *S. dumerili*, *S. lalandi*, *O. mykiss* ([Table 2](#)).<sup>149-155</sup>

Several phages for controlling *F. columnare*, which causes Columnaris disease in fish like *Clarias batrachus* and *O. Mykiss*, were isolated genetically and characterized.<sup>166</sup>

**Table 2. Morphology and genome characteristics of the fourteen phage families**

<i>Etiologic agent</i>	<i>Disease</i>	<i>Phage/Phages Cocktails</i>	<i>Fish/shellfish/ shrimp species</i>	<i>Outcomes</i>	<i>References</i>	
<i>Aeromonas salmonicida</i>	Furunculosis	HER 110	<i>Oncorhynchus fontinalis</i>	Use of bacteriophages has the potential to prevent of furunculosis in 3 days and to minimize the development of phage-resistant strains of <i>A.salmonicida</i> .	Imbeault et al. <sup>26</sup>	
	Furunculosis	O, R, B	<i>Salmo salar</i>	Phages were used orally, bath treatment and injection for therapy to <i>A.salmonicida</i> challenged fishes, but no protection was offered by any of the bacteriophage treatments.	Verner-Jeffreys et al. <sup>80</sup>	
	Furunculosis	PAS-1	<i>O.mykiss</i>	Phage PAS-1 showed efficient bacteriolytic activity. In tank experiments, the administration of infected fish exhibited notable protective effects and increasing survival rates.	Kim et al. <sup>81</sup> ; 2015	
	Furunculosis	AS-A	<i>Solea senegalensis</i>	Results showed that after 6 h of treatment the phage inhibited the growth of <i>A.salmonicida</i> both in batch cultures and seawater in the presence of fish juveniles.	Silva et al. <sup>82</sup>	
			SW69-9, L9-6, Riv-10	Fish	A new classification scheme for <i>A.salmonicida</i> phages.	Vincent et al. <sup>83</sup>
	Furunculosis	AS-A, AS-D, AS-E	-	-	Phage cocktails developed phage cocktails reduced the population of <i>A.salmonicida</i> faster than single suspensions.	Duarte et al. <sup>84</sup>
	Furunculosis	AS-szw, AS-yj, AS-zj, AS-sw, AS-gz	-	-	In vitro investigations into phages are prerequisite to obtain satisfying phage cocktails prior to application in practice.	Chen et al. <sup>85</sup>
	Furunculosis	ASP-1	<i>Carassius auratus</i>	ASP-1 phage was isolated and characterized. Phage was stable over wide-range of temperatures, pH and salinity. ASP-1 showed 30 min of latent period, 16 PFU/infected cells of burst size and 40 min of rise period.	Nikapitiya et al. <sup>86</sup>	
	Furunculosis	vB_AsM_ZHF, ZHA, ZHD	<i>Scophthalmus maximus</i>	3 <i>A.salmonicida</i> subsp. <i>masoucida</i> phage isolates from sewage, and vB_AsM_ZHF exhibited the best antibacterial effect, based on in vitro sexperiment.	Xu et al. <sup>87</sup>	
<i>A.hydrophila</i>	Motile Aeromonas, Hemorrhagic septicemia	AH1	pond water	First isolation of AH1 phage.	Wu et al. <sup>88</sup>	
	Motile Aeromonas	pAh1-C, pAh6-C	<i>Misgurnus anguillicaudatus</i>	Phages showed efficient bacteriolytic activity against fish-pathogenic <i>A.hydrophila</i> from loaches. The latent periods of the phages were estimated to be approximately 30 min (pAh1-C) and 20 min (pAh6-C).	Jun et al. <sup>89</sup>	
	Motile Aeromonas	ΦZH1 and ΦZH2	<i>Oreochromis niloticus</i>	ΦZH1 and ΦZH2 administered via injection was found to be effective in treating fish infected with <i>A.hydrophila</i> shown through the significant decrease in number of <i>A.hydrophila</i> found in the water of treated fish.	El-Araby et al. 2016	
	Motile Aeromonas	pAh-1	<i>Danio rerio</i>	pAh-1 as a lytic phage that strongly attacks the pathogenic <i>A.hydrophila</i> and higher survival rate of zebrafish.	Easwaran et al. <sup>90,91</sup>	

<i>Etiologic agent</i>	<i>Disease</i>	<i>Phage/Phages Cocktails</i>	<i>Fish/shellfish/shrimp species</i>	<i>Outcomes</i>	<i>References</i>
	Motile Aeromonas	AP1, AP2, AP3, AP4	<i>O. niloticus</i>	Results achieved 94% elimination of <i>A. hydrophila</i> comparing to phage infectivity under basal conditions. In vivo efficiency of AP2 against <i>A. hydrophila</i> invading the aquaria of Nile tilapia was investigated. Elimination of <i>A. hydrophila</i> in the rearing water was detected after 24h.	Hassan et al. <sup>92</sup>
	Motile Aeromonas	φF2, φF5	<i>Pangasianodon hypophthalmus</i>	Phage treatments applied to bacterial strains during infestation of catfish resulted in the survival rates of the tested fishes, with up to 100% compared to 18.3% survival observed in control experiments.	Le et al. <sup>93</sup>
	Motile Aeromonas	TG25P, CT45P	<i>P. hypophthalmus</i>	TG25P and CT45P were subjected to the phage cocktail to inactivate <i>A. hydrophila</i> .	Hoang et al. <sup>94</sup>
	Motile Aeromonas	PVN02	<i>P. hypophthalmus</i>	Confirmed that PVN02 is a novel lytic phage that could potentially be used as an agent to control <i>A. hydrophila</i> in striped catfish.	Tu et al. <sup>95,96</sup>
	Motile Aeromonas	Akh-2	<i>Misgurnus anguillicaudatus</i>	Isolated two phages that can infect <i>A. hydrophila</i> from seawater, isolation of more phages is promising, further isolation, characterization and application of <i>A. hydrophila</i> .	Akmal et al. <sup>97</sup>
	Motile Aeromonas	MJG	<i>O. mykiss</i>	MJG had activity at temperature 10 °C between 60 °C and pH 2 to 10, and its latent and rise periods were 30 and 40 min. MJG treatment would restore liver tissue damages and abolish the clinical signs of infection.	Cao et al. <sup>98</sup>
	Motile Aeromonas	pAh6.2TG	<i>O. niloticus</i>	The pAh6.2TG was highly specific to <i>A. hydrophila</i> and infected 83.3% tested strains of MDR <i>A. hydrophila</i> (10 out of 12) with relative stability at pH 7-9, temperature 0-40°C and salinity 0-40 ppt.	Dien et al. <sup>99</sup>
	Motile Aeromonas	PVN02	<i>P. hypophthalmus</i>	Without the existence of the phage, the highest mortality rate was 68.3 at the highest density of bacterial suspension and mortality rate at the highest density of bacterial suspension was significantly reduced to 8.33 ± 2.9% or 16.67 ± 2.9% at the phage dose of log 6.2 ± 0.09 or log 4.2 ± 0.09 PFU/g.	Dang et al. <sup>100</sup>
	Motile Aeromonas	AH-1, AH-4, and AH-5	<i>Cerastoderma edule</i>	All phages were effective against <i>A. hydrophila</i> , but phage AH-1 (with a maximum reduction of 7.7 log colonies forming units CFU/mL).	Duarte et al. <sup>101</sup>
	Motile Aeromonas	PZL-Ah1 and PZL-Ah8	Aquatic animal	PZL-Ah1 and PZL-Ah8 were isolated and used to decrease infection.	Yu et al. <sup>102</sup>
	Vibriosis	Ahy-Yong1	<i>Cyprinus aka Koi</i>	It is stable at 30–40 °C and at pH 2–12. Ahy-yong1 revealed an effective biofilm removal capacity and an obvious protective effect in brocade carp. In vitro and in vivo experiments demonstrated a high antibacterial rate of Ahy-yong1 against <i>A. hydrophila</i> .	Pan et al. <sup>103</sup>
<i>A. hydrophila</i> and <i>P. fluorescens</i>	Motile Aeromonas	50AhydR13PP, 60AhydR15PP, 25AhydR2PP, 22PfluR64PP, 67PfluR64PP,	<i>O. mykiss</i>	The use of mixed phages increased the activity of lysozyme, total protein and immunoglobulin level. Ceruloplasmin level in the fish serum remained unchanged. Killing and metabolic activity of spleen phagocytes and proliferation of pronephros lymphocytes were higher compared to the control group.	Schulz et al. <sup>104</sup>

Etiologic agent	Disease	Phage/Phages Cocktails	Fish/shellfish/shrimp species	Outcomes	References
		71PfluR64PP, 98PfluR60PP			
<i>A.punctata</i>	Septicemia, diarrhea, wound infections	IHQ1	Stream water	Characterization of phage IHQ1 showed that it was very efficient in lysing <i>A.punctata</i> , combined with its outstanding thermal and pH stability;	Haq et al. <sup>40</sup>
<i>A.hydrophila</i> and <i>Edwardsiella tarda</i>	Hemorrhagic septicaemia, Edwardsiellosis	A1,A2,E1,E2,T1,T2	<i>Anguilla japonica</i>	Phages decreased the bacterial host after 2 hours. In pond water, phage treatment reduced 250-fold the <i>A.hydrophila</i> population in 8 h, while phage population increased	Hsu et al. <sup>105</sup>
<i>E.tarda</i>	Edwardsiellosis	G1, G7, G8, G9.2	<i>P.hypophthalmus</i>	Phages latent period were 55-70 min and 28-160 PFU/cell. <i>E.ictaluri</i> was challenged in vitro in broth and was inactivated by single phage for 18-20 h.	Hoang and Pham <sup>94</sup>
	Edwardsiellosis	ET-1	<i>Anguilla japonica</i>	Phages for phage typing of <i>E.tarda</i> could not be found because 175 strains of <i>E. tarda</i> used in this study were divided into 15 phage types by 8 strains of phages and 87 strains of <i>E.tarda</i> were not sensitive to the phages.	Wu and Chao <sup>106</sup> ; Yamamoto and Maegawa <sup>107</sup>
	Edwardsiellosis	ETP-1	<i>D.rerio</i>	Zebrafish was bath exposed for 12 days to phage and challenged with <i>E.tarda</i> , the survival rate in 4 days.	Nikapitiya et al. <sup>108</sup>
	Ascites	PETp9, PVHp5	<i>Scophthalmus maximus</i>	The results showed that the abundance of <i>Vibrio</i> species and <i>Edwardsiella</i> species in turbot's intestine was significantly reduced by feeding with phage cocktails of <i>E.tarda</i> phage PETp9 and <i>V.harveyi</i> phage PVHp5.	Cui et al. <sup>109</sup>
	Edwardsiellosis	phage	<i>P.olivaceus</i>	<i>E.tarda</i> phages were identified in the seawater before the disease outbreak and during the disease prevalence, but not detected after the outbreak terminated.	Matsuoka and Nakaj <sup>110</sup>
<i>E.ictaluri</i>	Septisemia	φFeiDWF, φ FeiAU, φFeiMSLS	Channel catfish	Three <i>E.ictaluri</i> specific bacteriophages isolated from geographically distant aquaculture ponds, at different times, were sequenced and analyzed and these bacteriophages are lytic and can be used in infection diseases.	Walakira et al. <sup>111</sup> ; Carrias et al. <sup>112</sup>
<i>E.piscicida</i>	Edwardsiellosis	vB_EpM_ZHS, vB_EpP_ZHX	<i>S.maximus</i>	Cocktail phage significantly inhibited bacterial growth in vitro and decreased approximately 40% of mortality rate and an order of magnitude of bacterial burden in zebrafish and turbot infected by <i>E.piscicida</i> .	Xu et al. <sup>113</sup>
<i>Vibrio sp.</i>	Vibriosis	ValLY-3, VspDsh-1, VspSw-1, ValSw4-1, VpaJT-1,	<i>Litopenaeus vannamei</i>	Phage cocktail preparation showed in vitro higher efficiency in inhibiting the growth of <i>Vibrio sp.</i> Va-F3 than any single phage.	Chen et al. <sup>114</sup>
<i>Vibrio harveyi</i>	Luminescent vibriosis	Viha8, Viha10, Viha9, Viha11	<i>Penaeus monodon</i>	Phage Viha10 was effective in reducing the population of <i>V.harveyi</i> in the biofilm and application of phages Viha8 and Viha10 resulted in 85% survival of larvae	Karunasagar et al. <sup>115</sup>
	Vibriosis	Viha 1, Viha 2, Viha 3, Viha4, Viha 5, Viha 6,	<i>Penaeid shrimp</i>	Six phages were highly lytic for <i>V.harveyi</i> and they were potential candidates for biocontrol of this bacterium.	Shivu et al. <sup>116</sup>


Etiologic agent	Disease	Phage/Phages Cocktails	Fish/shellfish/shrimp species	Outcomes	References
		Viha 7,			
	Vibriosis	Siphoviridae	<i>P.monodon</i>	The study concluded that bacteriophage has the potential in management of luminous vibriosis in aquaculture.	Vinod et al. <sup>117</sup>
	Vibriosis	VH1, VH8	Shrimp	All the isolates of phage caused lysis of the host bacteria within 2 hours.	Srinivasan et al. <sup>118</sup>
	Vibriosis	VHM1, VHM2, VHS1	<i>P.monodon</i>	Post larval stages of shrimp were treated with bacterium (105 cells/mL) first in laboratory trials followed by single phage treatment about 109 PFU/mL and phage cocktail treatment about 109 PFU/mL. It can be used as a potential alternative treatment for the control <i>V.harveyi</i> in shrimp	Stalina and Srinivasan <sup>119</sup>
	Vibriosis	VhCCS-01, -02, -04, -06, -17, -20, -19, -21	<i>Panulirus ornatus</i>	The lytic ability of 6 phages suggested that they are appropriate for phage therapy.	Crothers-Stomps et al. <sup>120</sup>
	Vibriosis	PVHp5, PVHp8	<i>S.maximus L.</i>	Two phages are isolated and feeding phage cocktails may be another optimal therapeutic agent against <i>V.harveyi</i> infection in turbot	Cui et al. <sup>121</sup>
	Vibriosis	PW2	Shrimp	Phage performance depends on temperature and pH. Phage adsorption rate increased rapidly in 15 min of infection to 80% and continued to increase to 90% within 30 min of infection.	Phumkhachorn and Rattanachai-kunsopon <sup>122</sup>
	Vibriosis	VHLM	<i>P.monodon</i>	Phage showed a narrow host range and an apparent preference for <i>V.harveyi</i> rather than other 63 isolates and 10 other.	Oakey and Owens <sup>123</sup>
	Vibriosis	vB_VhaS-a, vB_VhaS	<i>Haliotis laevisgata</i>	Treatment with phages resulted in 70% of survival.	Wang et al. <sup>124</sup>
<i>V.parahaemolyticus</i>	Luminescent vibriosis	pVp-1	Oysters	Bath immersion and surface-application of the lytic phage effectively reduced the bacterial growth of <i>V.parahaemolyticus</i> .	Jun et al. <sup>125,126</sup>
	-	vB_VpS_BA3, vB-VpS_CA8	Sewage	In the in vitro phage trial CA8 had the potential for phage therapy.	Yang et al. <sup>127</sup>
	Vibriosis	A3S and Vpms1	<i>Litopenaeus vannamei</i>	Phages were reduce the mortality rates of larvae caused by <i>V.parahaemolyticus</i> , especially when applied at the early stage (6 h post-infection).	Lomelí-Ortega and Martínez-Díaz <sup>128</sup>
	Vibriosis	ΦVP-1	<i>Penaeid shrimp</i>	Ability to infect <i>V.parahaemolyticus</i> and <i>V.alginolyticus</i> and showing also biofilm reducing capacity.	Matamp and Bhat <sup>129</sup>
	Vibriosis	VPp1, VP-1, VP-2 and VP-3	Oysters	<i>V. parahaemolyticus</i> in oysters, which decreased by 2.35–2.76 logCFU/g within 36 h.	Rong et al. <sup>130</sup> ; Mateus et al. <sup>131</sup>
	Vibriosis	VP93, VpV262	-	Phage growth can be modelled if phage-sensitive and resistant cells that convert to each other with a high frequency are present in clonal cultures of pandemic <i>V.parahaemolyticus</i> .	Bastías et al. <sup>132</sup>
	Vibriosis	AMN2, FT2, FT3, KD1,V1, AMN1, AMN3, PL1, V2, V4, V5 and V6	<i>Litopenaeus vannamei</i>	Phage application against <i>V.parahaemolyticus</i> in shrimp showed 78.1% reduction in bacterial counts within 1 h.	Dubey et al. <sup>133</sup>



<b>Etiologic agent</b>	<b>Disease</b>	<b>Phage/Phages Cocktails</b>	<b>Fish/shellfish/ shrimp species</b>	<b>Outcomes</b>	<b>References</b>
	Vibriosis	VP1, VP7 and VP	<i>P.monodon</i>	The cumulative survival rate were 70% after 144 h and others 60–65% .	Alagappan et al. <sup>134</sup>
	Vibriosis	PVP1, PVP2	<i>Apostichopus japonicus</i>	Feeding phage cocktails might be another optimal therapeutic agents to treat <i>V. parahaemolyticus</i> infections in sea cucumber aquaculture.	Ren et al. <sup>135</sup>
<i>V.anguillarum</i>	Vibriosis	AS-1	Fish	Diseases controlled and efficacy of plating	Pereira et al. <sup>10</sup>
	Hemorrhagic septicemia	ALMED, CHOED, ALME, CHOD, CHOB	<i>Salmo salar</i>	Phages infect both <i>V.anguillarum</i> , <i>V.ordalii</i> but not <i>V.parahaemolyticus</i> , CHOED phage protect fish against experimentally induced vibriosis	Higuera et al. <sup>136</sup>
	Vibriosis	PVc-1, PVc-2	<i>Dicentrarchus labrax</i>	Genomic characterization were made by looking at genome size	Cagatay <sup>137</sup>
	Vibriosis	KVP40	<i>Gadus morhua L.</i> and <i>S.maximus L.</i>	Phage decreased mortality of cod and turbot larvae in experimental challenge assays with <i>V.anguillarum</i> pathogens suggested that phages can reduce <i>Vibrio</i> mortality in turbot and cod larvae.	Rørbo et al. <sup>138</sup>
	Vibriosis	VP-2, VA-1	<i>D.rerio</i>	Phage therapy is a suitable alternative approach against vibriosis in Zebra fish larvae.	Silva et al. <sup>139</sup>
<i>V.alginolyticus</i>	Vibriosis	φSt2 and φGrn1	Marine fish, live feeds (Artemia)	Phage cocktail live prey <i>A.salina</i> , led to 93% decrease of <i>Vibrio</i> population after 4 h of treatment in fish hatcheries.	Kalatzis et al. <sup>140</sup>
	Vibriosis	VEN	-	These results suggest that VEN may provide a good candidate to control recurrent diseases caused by <i>V.alginolyticus</i> .	Kokkari et al. <sup>141</sup>
<i>V.coralliilyticus</i>	Coral diseases	YC	<i>Acropora millepora</i>	Phage has isolated and identified a effective against the coral pathogen <i>V.coralliilyticus</i>	Cohen et al. <sup>142</sup>
	Mortality of larvae	pVco-14, pVco-5, pVco-7.	<i>Crassostrea gigas</i>	Higher survival rate in phage-treated oyster larvae	Kim et al. <sup>143,144</sup>
<i>V.splendidus</i>	Skin ulcer	vB_VspP_pVa5	Fish	The phage showed a huge bactericidal activity and proposed as potential phage cocktails and suitable for the biological control of <i>V.splendidus</i> .	Katharios et al. <sup>145</sup>
<i>Photobacterium damsela</i> formerly <i>Vibrio damsela</i>	Opportunistic pathogens	vB_Pd_PDCC-1	<i>Seriola rivoliana</i>	vB_Pd_PDCC-1 against <i>P. damsela</i> subsp. <i>damsela</i> was isolated and characterized. vB_Pd_PDCC-1 increased the hatching rate of eggs, and reduced presumptive bacterial species	Veyrand-Quir et al. <sup>146</sup>
<i>Pseudomonas plecoglossicida</i>	Hemorrhagic ascites	PPpW-3, PPpW-4	<i>Plecoglossus altivelis</i>	Mortalities of fish receiving PPpW-3, PPpW-4, PPpW-3/W were 53.3, 40.0, 20.0 and 93.3%, respectively when phage impregnated feed was used to ayu with disease decreased after a 2 wk period.	Park and Nakaj <sup>61</sup> ; Kawato et al. <sup>147</sup>
<i>Pseudomonas aeruginosa</i>	Aeromonas infection	Pseudomonas phage	<i>Clarias gariepinus</i>	First report of application of phage therapy against MBL producing <i>P.aeruginosa</i> isolated from aquatic ecosystem	Khairmar et al. <sup>148</sup>
<i>Lactococcus garvieae</i>	Lactococcosis	PLgT-1	Marine fish	The lysogenic phage PLgT-1 may be involved in the transfer of a virulence factor into <i>L.garvieae</i> strains colonizing marine fish in Japan	Hoai and Yoshida <sup>149</sup>
	Lactococcosis	PLgY-16, PLgY-30, PLgW-1	<i>Seriola quinqueradiata</i>	Phage administered either intraperitoneally or orally protected fish from <i>L.garvieae</i> infection.	Nakai et al. <sup>150</sup> ; Park et al. <sup>151,152</sup>
	Lactococcosis	PLgY-30	<i>S.quinqueradiata</i>	The complete sequence of <i>L.garvieae</i> phage PLgY-30 was obtained	Hoai et al. <sup>153</sup>

<i>Etiologic agent</i>	<i>Disease</i>	<i>Phage/Phages Cocktails</i>	<i>Fish/shellfish/ shrimp species</i>	<i>Outcomes</i>	<i>References</i>
	Lactococcosis	PLG-II	<i>S. quinqueradiata</i> , <i>S. dumerili</i> , <i>S. lalandi</i>	Genomics analysis suggests that phage PLG-II might represent a novel species in the genus Uwajimavirus. phage PLG-II a suitable candidate for control of <i>L.garvieae</i> serotype II fish infections.	Akmal et al. <sup>154</sup>
	Lactococcosis	WWP-1	<i>O.mykiss</i>	Phage WWP-1 represented optimal antibacterial activity at temperatures ranging from 15 to 30 C, suggesting that it could be very effective at rainbow trout rearing temperature. In vivo experiment result, WWP1 could decrease mortality rate of infected rainbow trout in aquaculture.	Ghasemi et al. <sup>155</sup>
<i>Streptococcus iniae</i>	Streptococcosis	PSIJ-31, PSIJ-32, PSIJ-41, PSIJ-42, PSIJ-51, PSIJ-52	<i>Paralichthys olivaceus</i>	Fish were injected intraperitoneally with bacteria and 1 h later IP-injected with a mixture of two or four phage isolates and observed at 25°C for 2 wk. Mortalities of fish receiving phages were significantly lower than those of control fish without phage-treatment.	Matsuoka et al. <sup>156</sup>
<i>Yersinia ruckeri</i>	Enteric redmouth disease, yersiniosis	φ 2, φ 3, φ 3, φ 9,	<i>S.salar</i>	4 different phages and a cocktail with a combination of the four was tested. Non-vaccinated fish had no phage reactive antibodies but inactivated phages were highly immunogenic for salmon and a good specific anti-phage antibody response was obtained in immunized salmon.	Strand <sup>157</sup>
	Enteric redmouth disease, yersiniosis	YerA41	Salmonid fish	YerA41 genome sequence were determined, we performed RNA sequencing from phage cells at different time infection.	Leskinen et al. <sup>158</sup>
	Enteric redmouth disease, yersiniosis	φNC10	<i>O.mykiss</i>	The φNC10 associated polysaccharide depolymerase activity reduced the ability of <i>Y.ruckeri</i> cells to cause mortality following intraperitoneal injection into fish. Potential usage of φNC10 for <i>Y.ruckeri</i> infection.	Welch <sup>159</sup>
<i>Flavobacterium columnare</i>	Columnaris disease	FCP1, FCP9, FCP1	<i>Clarias batrachus</i>	Phage treatment led to disappearance of gross symptoms, negative bacteriological test, detectable phage and 100% survival in experimentally infected <i>C.batrachus</i> that was treated with a virulent bacteria and FCP1 a significant decrease in fishes.	Prasad and Kumar <sup>160</sup> ; Prasad et al. <sup>161</sup>
	Columnaris disease	FKj-2, FL-1, FCL-2, FCV-1	<i>O.mykiss</i> , <i>D.rerio</i>	Phages infecting <i>F.columnare</i> were isolated only from fish farms during disease outbreaks. 100% of the zebrafish and 50% of the rainbow trout survived in the phage treatment.	Laanto et al. <sup>162,163</sup>
	Columnaris disease	FCO-F2 to FCOV-F2, FCOV-F5, COV-F25, FCO-F9 to FCL-2, FCOV-F13, FCOV-F45	Salmonid	Bacterial infection decreased in the exposure cultures but started to increase after 1 to 2 days, along with a change in colony morphology from original rhizoid to rough.	Kunttu et al. <sup>164</sup>
	Columnaris disease	PFlc-1 ve PFlc-2	<i>Carassius auratus</i>	Genomic characterization were made by looking at genome size	Cagatay <sup>165</sup>
	Columnaris	FCOV-S1 to 62	aquaculture	Examined phenotypic and genetic characteristics 63 phages from fish	Runtuvuori-Salmela et

<b>Etiologic agent</b>	<b>Disease</b>	<b>Phage/Phages Cocktails</b>	<b>Fish/shellfish/ shrimp species</b>	<b>Outcomes</b>	<b>References</b>
	disease		environments	farms in Finland and Sweden.	al. <sup>166</sup>
<i>F. psychrophilum</i>	Rainbow trout fry syndrome, bacterial coldwater disease	FpV-1 to FpV-22, FpV2, FpV4, FpV7, FpV9, FpV10, FpV14, FpV19	<i>O. mykiss</i>	Phages with strong lytic potential against <i>F. psychrophilum</i> host strains thus provided the foundation for future exploration of the potential of phages in the treatment of both diseases.	Stenholm et al. <sup>167</sup>
	Rainbow trout fry syndrome	PFpW-3, PFpC-Y, PFpW-6, PFpW-7, PFpW-8	<i>Plecoglossus altivelis altivelis</i>	Among the phages, in in vitro assays, PFpW-3 displayed high infectivity for <i>F. psychrophilum</i> isolated from ayu fish, indicating that it could have treatment of diseases	Kim et al. <sup>168</sup>
	bacterial coldwater disease	1H, 6H, 9H, 2P, 23T, 2A, FpV4, FpV9	<i>S. salar</i> , <i>O. mykiss</i>	15 bacteriophages able to infect some of the <i>F. psychrophilum</i> isolates and characterized six of them in detail. Phages were injected i.p. in a ratio of 10:1 (PFU: CFU) and significantly decrease fish mortality.	Castillo et al. <sup>169</sup>
	Rainbow trout fry syndrome	FpV-4 and FpV-9	<i>O. mykiss</i>	Diet with phage additives might be a method for delivery of phages to <i>F. psychrophilum</i> -infected fish. the potential of phages to spread to inner organs of rainbow trout after i.p. injection and to proliferate and maintain infectivity for up to 10 days.	Madsen et al. <sup>170</sup>
	Rainbow trout fry syndrome, bacterial coldwater disease	FpV-9	<i>O. mykiss</i>	Survival of FpV-9 in vivo in juvenile fish after by bath, oral intubation into the stomach and phage-coated feed. Phages via coated feed pellets constitutes a promising method of treatment and prevention of diseases.	Christiansen et al. <sup>171</sup>
	Rainbow trout fry syndrome	FpV4 and FPSV-D22	<i>O. mykiss</i>	The delivery of phages to fish organs by oral, suggests that higher phage dosages on feed pellets to offer fish an adequate protection against <i>F. psychrophilum</i> infections.	Donati et al. <sup>172,173</sup>



**Figure 2. Schematic steps on phage application in aquaculture.**

1. Phages are isolated from ponds or aquatic animals 2. Phages are isolated, purified, and identified 3. Phage is added to the farm water/fish/hatchery 4. After adding phages to water, they attach and contact the infected bacterial pathogen and then undergo a lytic cycle. Phage DNA would penetrate the host bacteria and replicate, transcription, and translation. Then the phage would assemble, the fish pathogen would be lysed, and phages would be released from the pathogen bacteria 5. Lysis of fish pathogen bacteria 6. Results of phage therapy in fish diseases.

Application of columnar phages (FCP1, FCP9, and FCP1) to infected fish resulted in the resolution of disease symptoms and stopped infection.<sup>160,161</sup> Four phages infecting *F. columnare* were isolated from fish farms during columnaris outbreaks. The zebrafish (100%) and the rainbow trout (50%) survived after the phage treatment.<sup>162,163</sup> Furthermore, several studies reported isolation and application for *F. psychrophilum* phages that could be used for biocontrol of the fry syndrome and cold water disease in *S. salar*, *O. Mykiss*, and *P. altivelis*. Lytic phages against *F. psychrophilum* strains provided the future potential in the treatment of this disease (Table 2).<sup>167-173</sup>

The therapeutic effects of six *S. iniae* lytic phages with dsDNA were studied against *Streptococcus* infection in *P. olivaceus* at 25°C for 2 weeks (Table 2).<sup>156</sup>

*Y. ruckeri* is the causative bacterium of yersiniosis, known as enteric red mouth disease in freshwater salmonid fish. Yer A41,  $\phi$  2,  $\phi$  3,  $\phi$  3,  $\phi$  9 and  $\phi$ NC10 phages were tested as a combined or single intraperitoneal injection to treat *Y. ruckeri* and antibody production was reported in phage-treated fish (Table 2).<sup>157-159</sup>

Two phages, named PT2 and phiKMV, were obtained from sewage, identified, and treated for *P. aeruginosa* infection at the surface of *C. gariepinus*. It was observed that

the number of infective lesions decreased after 8-10 days in phage-treated fish.<sup>148</sup>


Similarly, phages, namely PpW-3 and PpW-4, were used to treat bacterial hemorrhagic ascites disease caused by *P. plecoglossicida* in *P. altivelis*.<sup>61,147</sup>

There are a few studies reported that specific phages of *E. tarda*, *E. ictaluri*, and *E. piscicida* stop especially growth of bacteria and reduce edwardsiellosis in vitro in *D. rerio*, *P. hypophthalmus*, *A. japonica* and *S. maximus*.<sup>94,106-113</sup>

Various *Vibrio* species, such as *V. harveyi*, *V. vulnificus*, *V. anguillarum*, *V. parahaemolyticus*, *V. alginolyticus*, *V. coralliilyticus*, *V. splendidus*, and *P. damsela* (formerly *V. damsela*) are the cause of vibriosis have also been controlled by vibriophages which is biocontrol agents in fish (*S. maximus* L., *S. salar*, *D. labrax*, *D. rerio*, *G. morhua* L.) and *P. monodon*, *L. vannamei*, *P. ornatus*, *H. laevigata*, *A. japonicus*.<sup>187</sup> Studies have reported that approximately 60 bacteriophages were morphologically identified and genome sequenced and applied against *Vibrio* strains with no side effects shown in Table 2.<sup>10,114-118,121,127-131,134,138,140,145,146,165</sup>

## CONCLUSION

Despite good management practices, chemotherapeutic and prophylactic applications such as vaccines and various



**Figure 3. Publication related to phage therapy in aquaculture over 25 years.**

The bar indicates the number of the Web of Science search for publications related to phage therapy and genomes associated with the most important fish pathogens *A. hydrophila*, *A. salmonicida*, *E. tarta*, *V. harveyi*, *V. parahaemolyticus*, *V. anguillarum*, *V. alginolyticus*, *F. columnare*, *F. psychrophilum*, *Y. ruckeri*, *L. Garviae*, and *S. iniae* in the last 25 years.

antibiotics for producing fish, crustaceans, and mollusks in many countries where aquaculture is a vital economic resource, bacterial diseases still stay a severe problem as they cause high mortality rates. An additional problem of bacterial infection is nowadays not only bacterial resistance to antibiotics but also the use of all known antibiotics in the treatment. Therefore, phage therapy has been shown as a perfect and valid option for antibiotic treatment. It is also an environmentally friendly, relatively rapid, simple administration, and inexpensive approach to disease prevention and control in aquaculture. Furthermore, therapeutic and prophylactic phage applications in aquaculture can effectively inactivate and eliminate pathogenic bacteria without harming useful microbiota and are easy to apply at various stages of vertebrates or invertebrates. Most of the aquaphage studies of the last 40 years, which we reviewed in this article, showed us that phage therapy has a general protective effect and can be substituted for possible antibiotics (Table 2). From the author's perspective, although phage applications provide an optimistic view of future benefits for disease prevention and treatment in the world

aquaculture sector, caution is required as the potential evolution of phage resistance against bacterial agents may also be present. In addition, more field applications should be made with large-scale cultivation and long-term preservation, and standardized methods and formulations should be developed. Furthermore, new commercially patented aquaphage products must be developed for future aquaculture practice. More research and improvement in phage therapy will play a significant role in sustainable aquaculture globally.

#### AUTHOR CONTRIBUTIONS

Conceptualization: Ifakat T. Çağatay (Lead). Investigation: Ifakat T. Çağatay (Lead). Writing – review & editing: Ifakat T. Çağatay (Lead).

Submitted: March 21, 2023 CDT, Accepted: April 17, 2023 CDT



This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CCBY-NC-ND-4.0). View this license's legal deed at <https://creativecommons.org/licenses/by-nc-nd/4.0> and legal code at <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> for more information.

## REFERENCES

1. Fazio F. Fish hematology analysis as an important tool of aquaculture: a review. *Aquaculture*. 2019;500:237-242. [doi:10.1016/j.aquaculture.2018.10.030](https://doi.org/10.1016/j.aquaculture.2018.10.030)
2. FAO. *The State of World Fisheries and Aquaculture 2020*. FAO; 2020.
3. Żaczek M, Weber-Dąbrowska B, Górski A. Phages as a cohesive prophylactic and therapeutic approach in aquaculture systems. *Antibiotics*. 2020;9(9):564. [doi:10.3390/antibiotics9090564](https://doi.org/10.3390/antibiotics9090564)
4. Alderman DJ. Geographical spread of bacterial and fungal diseases of crustaceans. *Rev Sci Tech OIE*. 1996;15(2):603-632. [doi:10.20506/rst.15.2.943](https://doi.org/10.20506/rst.15.2.943)
5. Shao ZJ. Aquaculture pharmaceuticals and biologicals: current perspectives and future possibilities. *Advanced Drug Delivery Review*. 2001;50(3):229-243. [doi:10.1016/s0169-409x\(01\)00159-4](https://doi.org/10.1016/s0169-409x(01)00159-4)
6. Stickney RR. Diseases of aquaculture species. In: Stickney RR, ed. *Aquaculture: An Introductory Text*. CABI; 2009:148-173. [doi:10.1079/9781845935894.0148](https://doi.org/10.1079/9781845935894.0148)
7. Dy RL, Rigano LA, Fineran PC. Phage-based biocontrol strategies and their application in agriculture and aquaculture. *Biochemical Society Transactions*. 2018;46(6):1605-1613. [doi:10.1042/bst20180178](https://doi.org/10.1042/bst20180178)
8. Austin B, Austin DA. *Bacterial Fish Pathogens: Disease of Farmed and Wild Fish*. 26,552. Springer International Publishing; 2016. [doi:10.1007/978-3-319-32674-0](https://doi.org/10.1007/978-3-319-32674-0)
9. Nokhwal A, Anand T, Vaid RK. Bacteriophage therapy: an emerging paradigm in fish disease management. *Aquacult Int*. 2022;31(2):777-805. [doi:10.1007/s10499-022-01001-7](https://doi.org/10.1007/s10499-022-01001-7)
10. Pereira C, Silva YJ, Santos AL, Cunha Â, Gomes NCM, Almeida A. Bacteriophages with potential for inactivation of fish pathogenic bacteria: survival, host specificity and effect on bacterial community structure. *Marine Drugs*. 2011;9(11):2236-2255. [doi:10.3390/md9112236](https://doi.org/10.3390/md9112236)
11. Richards GP. Bacteriophage remediation of bacterial pathogens in aquaculture: a review of the technology. *Bacteriophage*. 2014;4(4):e975540. [doi:10.4161/21597081.2014.975540](https://doi.org/10.4161/21597081.2014.975540)
12. Pal S. Phage therapy an alternate disease control in Aquaculture: A review on recent advancements. *Journal Agricultural Veterinary Sciences*. 2015;8:68-81. [doi:10.9790/2380-08916881](https://doi.org/10.9790/2380-08916881)
13. Roy A, Biswas A, Ghosh SK, Kim H, Swain S. Current scenario of antibiotic-resistance in Indian aquaculture. *Pharma Innovation Journal*. 2021;10(7):454-461.
14. Carrias A, Ran C, Terhune JS, Liles MR. Bacteria and bacteriophages as biological agents for disease control in aquaculture. *Infectious Disease in Aquaculture*. Published online 2012:353-393. [doi:10.1533/9780857095732.3.353](https://doi.org/10.1533/9780857095732.3.353)
15. Oliveira J, Castilho F, Cunha A, Pereira MJ. Bacteriophage therapy as a bacterial control strategy in aquaculture. *Aquacult Int*. 2012;20(5):879-910. [doi:10.1007/s10499-012-9515-7](https://doi.org/10.1007/s10499-012-9515-7)
16. Lelin C, Thirumalaikumar E, Uma G, et al. Isolation and partial characterization of bacteriophages infecting *Vibrio harveyi* from shrimp farm effluent water. *Aquacult Int*. 2022;30(4):2081-2094. [doi:10.1007/s10499-022-00891-x](https://doi.org/10.1007/s10499-022-00891-x)
17. Elbreki M, Ross RP, Hill C, O'Mahony J, McAuliffe O, Coffey A. Bacteriophages and their derivatives as biotherapeutic agents in disease prevention and treatment. *Journal of Viruses*. Published online March 26, 2014:1-20. [doi:10.1155/2014/382539](https://doi.org/10.1155/2014/382539)
18. Poluri KM, Sitthisak S, Khairnar K, Czajkowski R. Bacteriophages isolation from the environment and their antimicrobial therapeutic potential. *Front Microbiol*. 2021;12. [doi:10.3389/fmicb.2021.649334](https://doi.org/10.3389/fmicb.2021.649334)
19. Kowalska JD, Kazmierczak J, Sowińska PM, Wójcik EA, Siwicki AK, Dasty J. Growing trend of fighting infections in aquaculture environment-opportunities and challenges of phage therapy. *Antibiotics*. 2020;9(6):301. [doi:10.3390/antibiotics9060301](https://doi.org/10.3390/antibiotics9060301)
20. Schulz P, Pajdak-Czaus J, Siwicki AK. In vivo bacteriophages' application for the prevention and therapy of aquaculture animals. *Chosen Aspects Animals*. 2022;12(10):1233. [doi:10.3390/ani12101233](https://doi.org/10.3390/ani12101233)
21. Liu R, Han G, Li Z, et al. Bacteriophage therapy in aquaculture: Current status and future challenges. *Folia Microbiol*. 2022;67(4):573-590. [doi:10.1007/s1223-022-00965-6](https://doi.org/10.1007/s1223-022-00965-6)

22. Kahn LH, Bergeron G, Bourassa MW, et al. From farm management to bacteriophage therapy: strategies to reduce antibiotic use in animal agriculture. *Annals of the New York Academy of Sciences*. 2019;1441(1):31-39. [doi:10.3390/antibiotics12020417](https://doi.org/10.3390/antibiotics12020417)
23. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage Therapy. *Antimicrob Agents Chemother*. 2001;45(3):649-659. [doi:10.1128/aac.45.3.649-659.2001](https://doi.org/10.1128/aac.45.3.649-659.2001)
24. Lu TK, Collins JJ. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. *Proc Natl Acad Sci USA*. 2009;106(12):4629-4634. [doi:10.1073/pnas.0800442106](https://doi.org/10.1073/pnas.0800442106)
25. Jin J, Li ZJ, Wang SW, et al. Isolation and characterization of ZZ1, a novel lytic phage that infects *Acinetobacter baumannii* clinical isolates. *BMC Microbiol*. 2012;12(1):1-8. [doi:10.1186/1471-2180-12-156](https://doi.org/10.1186/1471-2180-12-156)
26. Imbeault S, Parent S, Lagacé M, Uhland CF, Blais JF. Using bacteriophages to prevent furunculosis caused by *Aeromonas salmonicida* in farmed brook trout. *Journal of Aquatic Animal Health*. 2006;18(3):203-214. [doi:10.1577/h06-019.1](https://doi.org/10.1577/h06-019.1)
27. Efrony R, Loya Y, Bacharach E, Rosenberg E. Phage therapy of coral disease. *Coral Reefs*. 2006;26(1):7-13. [doi:10.1007/s00338-006-0170-1](https://doi.org/10.1007/s00338-006-0170-1)
28. Salifu SP, Casey SAC, Foley S. Isolation and characterization of soilborne virulent bacteriophages infecting the pathogen *Rhodococcus equi*. *J Appl Microbiol*. 2013;114(6):1625-1633. [doi:10.1111/jam.12194](https://doi.org/10.1111/jam.12194)
29. Ackermann HW. Bacteriophage taxonomy. *Microbiol Aust*. 2011;32(2):90. [doi:10.1071/ma11090](https://doi.org/10.1071/ma11090)
30. Sieiro C, Areal-Hermida L, Pichardo-Gallardo Á, et al. A hundred years of bacteriophages: can phages replace antibiotics in agriculture and aquaculture? *Antibiotics*. 2020;9(8):493. [doi:10.3390/antibiotics9080493](https://doi.org/10.3390/antibiotics9080493)
31. Fathima B, Archer AC. Bacteriophage therapy: recent developments and applications of a renaissance weapon. *Research in Microbiology*. 2021;172(6):103863. [doi:10.1016/j.resmic.2021.103863](https://doi.org/10.1016/j.resmic.2021.103863)
32. Ackermann HW. Tailed bacteriophages: the order caudovirales. *Advances in Virus Research*. 1998;51:135-201. [doi:10.1016/s0065-3527\(08\)60785-x](https://doi.org/10.1016/s0065-3527(08)60785-x)
33. Ackermann HW. Classification of bacteriophages. *The bacteriophages*. 2006;2:8-16.
34. Sharp R. Bacteriophages: biology and history. *J Chem Technol Biotechnol*. 2001;76(7):667-672. [doi:10.1002/jctb.434](https://doi.org/10.1002/jctb.434)
35. Jeney F. *Controversy in Virology: Bacteriophage Therapy versus Antibiotics*. Trinity's Journals and Serial Publications; 2012.
36. Ge H, Fu S, Guo H, et al. Application and challenge of bacteriophage in the food protection. *International Journal of Food Microbiology*. 2022;380:109872. [doi:10.1016/j.ijfoodmicro.2022.109872](https://doi.org/10.1016/j.ijfoodmicro.2022.109872)
37. Borysowski J, Górski A. Is phage therapy acceptable in the immunocompromised host? *International Journal of Infectious Diseases*. 2008;12(5):466-471. [doi:10.1016/j.ijid.2008.01.006](https://doi.org/10.1016/j.ijid.2008.01.006)
38. Atterbury RJ. Bacteriophage biocontrol in animals and meat products. *Microbial Biotechnology*. 2009;2(6):601-612. [doi:10.1111/j.1751-7915.2009.00089.x](https://doi.org/10.1111/j.1751-7915.2009.00089.x)
39. Chhibber S, Kumari S. Application of therapeutic phages in medicine. *Bacteriophages*. Published online March 14, 2012:139-158. [doi:10.5772/34296](https://doi.org/10.5772/34296)
40. Haq IU, Chaudhry WN, Akhtar MN, Andleeb S, Qadri I. Bacteriophages and their implications on future biotechnology: a review. *Virology Journal*. 2012;9:1-9. [doi:10.1186/1743-422X-9-9](https://doi.org/10.1186/1743-422X-9-9)
41. Culot A, Grosset N, Gautier M. Overcoming the challenges of phage therapy for industrial aquaculture: A review. *Aquaculture*. 2019;513:734423. [doi:10.1016/j.aquaculture.2019.734423](https://doi.org/10.1016/j.aquaculture.2019.734423)
42. Guo Z, Lin H, Ji X, et al. Therapeutic applications of lytic phages in human medicine. *Microbial Pathogenesis*. 2020;142:104048. [doi:10.1016/j.micpat.2020.104048](https://doi.org/10.1016/j.micpat.2020.104048)
43. Twort FW. An investigation on the nature of ultra-microscopic viruses. *Lancet*. 1915;2:1241-1243.
44. d'Herelle F. Sur un microbe invisible antagonistic des bacilles dysentérique. *C R Acad Sci Paris*. 1917;165:373-375.
45. McKinley EB. The bacteriophage in the treatment of infections. *Arch Intern Med*. 1923;32(6):899. [doi:10.1001/archinte.1923.00110240092005](https://doi.org/10.1001/archinte.1923.00110240092005)
46. Kutter E, Sulakvelidze A. *Bacteriophages: Biology and Applications*. CRC Press; 2004. [doi:10.1201/9780203491751](https://doi.org/10.1201/9780203491751)

47. Lu TK, Koeris MS. The next generation of bacteriophage therapy. *Current Opinion in Microbiology*. 2011;14(5):524-531. doi:10.1016/j.mib.2011.07.028
48. Cisek AA, Dąbrowska I, Gregorczyk KP, Wyzewski Z. Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. *Curr Microbiol*. 2016;74(2):277-283. doi:10.1007/s00284-016-1166-x
49. Summers WC. Bacteriophage therapy. *Annu Rev Microbiol*. 2001;55(1):437-451. doi:10.1146/annurev.micro.55.1.437
50. Summers WC. The strange history of phage therapy. *Bacteriophage*. 2012;2(2):130-133. doi:10.4161/bact.20757
51. Bruynoghe R, Maisin J. Essais de thérapie au moyen du bacteriophage. *CR Soc Biology*. 1921;85:1120-1121.
52. Kazhal N, Iftimovich R. *From the History of Fight Against Bacteria and Viruses*. Nauchnoe Izdatelstvo; 1968.
53. Tsulukidze AP. Phage treatment in surgery. *Surgery ("Khirurgia")*. 1940;12:132-133.
54. Agafonov BI, Khokhlov DT, Zolochovsky MA. Epidemiology of typhoid paratyphoid infections and their prophylactics. *Military Medicine Journal*. 1984;6:36-40.
55. Chanishvili N. Phage therapy history from Twort and d'Herelle through Soviet experience to current approaches. *Advanced Virus Research*. 2012;83:3-40. doi:10.1016/b978-0-12-394438-2.00001-3
56. Smith HW, Huggins MB, Shaw KM. Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. *Microbiology*. 1987;133(5):1127-1135. doi:10.1099/0021287-133-5-1127
57. Matsuzaki S, Rashel M, Uchiyama J, et al. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. *Journal Infection and Chemotherapy*. 2005;11(5):211-219. doi:10.1007/s10156-005-0408-9
58. Kutter E, De Vos D, Gvasalia G, et al. Phage therapy in clinical practice: Treatment of human infections. *CPB*. 2010;11(1):69-86. doi:10.2174/138920110790725401
59. Clark JR. Bacteriophage therapy: history and future prospects. *Future Virology*. 2015;10(4):449-461. doi:10.2217/fvl.15.3
60. Palaniappan R, Dayanithi G. Therapeutic efficacy of bacteriophages. In: *Bacteriophages in Therapeutics*. IntechOpen; 2021. doi:10.5772/intechopen.97619
61. Park S, Nakai T. Bacteriophage control of *Pseudomonas plecoglossicida* infection in ayu, *Plectoglossis altivelis*. *Dis Aquat Org*. 2003;53(1):33-39. doi:10.3354/dao053033
62. Lomeli-Ortega CO, Balcázar JL, Quiroz-Guzmán E. Phage therapy and aquaculture: progress and challenges. *Int Microbiol*. 2022;26(2):439-441. doi:10.1007/s10123-022-00304-2
63. Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: From biological mechanisms to future directions. *Cell*. 2023;186(1):17-31. doi:10.1016/j.cell.2022.11.017
64. Svircev A, Roach D, Castle A. Framing the future with bacteriophages in agriculture. *Viruses*. 2018;10(5):218. doi:10.3390/v10050218
65. D'Accolti M, Soffritti I, Mazzacane S, Caselli E. Bacteriophages as a potential 360-degree pathogen control strategy. *Microorganisms*. 2021;9(2):261. doi:10.3390/microorganisms9020261
66. Alomari MMM, Dec M, Urban-Chmiel R. Bacteriophages as an alternative method for control of zoonotic and foodborne pathogens. *Viruses*. 2021;13(12):2348. doi:10.3390/v13122348
67. Withey S, Cartmell E, Avery LM, Stephenson T. Bacteriophages—potential for application in wastewater treatment processes. *Science Total Environment*. 2005;339(1-3):1-18. doi:10.1016/j.scitotenv.2004.09.021
68. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. *Future Microbiology*. 2013;8(6):769-783. doi:10.2217/fmb.13.47
69. Khalifa L, Brosh Y, Gelman D, et al. Targeting *Enterococcus faecalis* biofilms with phage therapy. *Appl Environ Microbiol*. 2015;81(8):2696-2705. doi:10.1128/aem.00096-15
70. Tian F, Li J, Nazir A, Tong Y. Bacteriophage a promising alternative measure for bacterial biofilm control. *IDR*. 2021;Volume 14:205-217. doi:10.2147/idr.s290093
71. Tolba M, Minikh O, Brovko LY, Evoy S, Griffiths MW. Oriented immobilization of bacteriophages for biosensor applications. *Appl Environ Microbiol*. 2010;76(2):528-535. doi:10.1128/aem.02294-09



72. Zeng Y, Wang Z, Zou T, et al. Bacteriophage as an alternative to antibiotics promotes growth performance by regulating intestinal inflammation, intestinal barrier function and gut microbiota in weaned piglets. *Front Vet Sci*. 2021;8:623899. doi:10.3389/fvets.2021.623899
73. Liang S, Qi Y, Yu H, et al. Bacteriophage Therapy as an Application for Bacterial Infection in China. *Antibiotics*. 2023;12(2):417. doi:10.3390/antibiotics12020417
74. Nakai T, Park SC. Bacteriophage therapy of infectious diseases in aquaculture. *Research of Microbiology*. 2002;153(1):13-18. doi:10.1016/s0923-2508(01)01280-3
75. Nakai T. Application of bacteriophages for control of infectious diseases in aquaculture. In: Sabour PM, Griffiths MW, eds. *Bacteriophages in the Control of Food- and Waterborne Pathogens*. American Society for Microbiology Press; 2014:257-272. doi:10.1128/9781555816629.ch13
76. Almeida A, Cunha Â, Gomes NC, Alves E, Costa L, Faustino MA. Phage therapy and photodynamic therapy: low environmental impact approaches to inactivate microorganisms in fish farming plants. *Marine Drugs*. 2009;7(3):268-313. doi:10.3390/md7030268
77. Choudhury GT, Tharabenahalli Nagaraju V, Gita S, Paria A, Parhi J. Advances in bacteriophage research for bacterial disease control in aquaculture. *Reviews in Fisheries Science & Aquaculture*. 2016;25(2):113-125. doi:10.1080/23308249.2016.1241977
78. Ninawe AS, Sivasankari S, Ramasamy P, Kiran GS, Selvin J. Bacteriophages for aquaculture disease control. *Aquacult Int*. 2020;28(5):1925-1938. doi:10.1007/s10499-020-00567-4
79. Nachimuthu R, Royam MM, Manohar P, Leptihn S. Application of bacteriophages and endolysins in aquaculture as a biocontrol measure. *Biological Control*. 2021;160:104678. doi:10.1016/j.biocontrol.2021.104678
80. Verner-Jeffreys DW, Algoet M, Pond MJ, Virdee HK, Bagwell NJ, Roberts EG. Furunculosis in Atlantic salmon (*Salmo salar* L.) is not readily controllable by bacteriophage therapy. *Aquaculture*. 2007;270(1-4):475-484. doi:10.1016/j.aquaculture.2007.05.023
81. Kim JH, Son JS, Choi YJ, et al. Isolation and characterization of a lytic Myoviridae bacteriophage PAS-1 with broad infectivity in *Aeromonas salmonicida*. *Curr Microbiol*. 2012;64(5):418-426. doi:10.1007/s00284-012-0091-x
82. Silva YJ, Moreirinha C, Pereira C, et al. Biological control of *Aeromonas salmonicida* infection in juvenile Senegalese sole (*Solea senegalensis*) with Phage AS-A. *Aquaculture*. 2016;450:225-233. doi:10.1016/j.aquaculture.2015.07.025
83. Vincent AT, Paquet VE, Bernatchez A, Tremblay DM, Moineau S, Charette SJ. Characterization and diversity of phages infecting *Aeromonas salmonicida* subsp. *salmonicida*. *Sci Rep*. 2017;7(1):1-10. doi:10.1038/s41598-017-07401-7
84. Duarte J, Pereira C, Moreirinha C, et al. New insights on phage efficacy to control *Aeromonas salmonicida* in aquaculture systems: An in vitro preliminary study. *Aquaculture*. 2018;495:970-982. doi:10.1016/j.aquaculture.2018.07.002
85. Chen L, Yuan S, Liu Q, et al. In vitro design and evaluation of phage cocktails against *Aeromonas salmonicida*. *Front Microbiol*. 2018;9:1476. doi:10.3389/fmicb.2018.01476
86. Nikapitiya C, Dananjaya SHS, Chandrarathna HPSU, Senevirathne A, De Zoysa M, Lee J. Isolation and characterization of multidrug resistance *Aeromonas salmonicida* subsp. *salmonicida* and its infecting novel phage ASP-1 from goldfish (*Carassius auratus*). *Indian J Microbiol*. 2019;59(2):161-170. doi:10.1007/s12088-019-00782-5
87. Xu Z, Jin P, Zhou X, et al. Isolation of a virulent *Aeromonas salmonicida* subsp. *masoucida* bacteriophage and its application in phage therapy in turbot (*Scophthalmus maximus*). *Appl Environ Microbiol*. 2021;87(21):01468-21. doi:10.1128/aem.01468-21
88. Wu JL, Lin HM, Jan L, Hsu YL, Chang LH. Biological control of fish bacterial pathogen *Aeromonas hydrophila*, by bacteriophage AH1. *Fish Pathol*. 1981;15(3-4):271-276. doi:10.3147/jfsfp.15.271
89. Jun JW, Kim JH, Shin SP, Han JE, Chai JY, Park SC. Protective effects of the *Aeromonas* phages pAh1-C and pAh6-C against mass mortality of the cyprinid loach (*Misgurnus anguillicaudatus*) caused by *Aeromonas hydrophila*. *Aquaculture*. 2013;416-417:289-295. doi:10.1016/j.aquaculture.2013.09.045
90. Easwaran M, Dananjaya SHS, Park SC, Lee J, Shin HJ, De Zoysa M. Characterization of bacteriophage pAh-1 and its protective effects on experimental infection of *Aeromonas hydrophila* in Zebrafish (*Danio rerio*). *J Fish Dis*. 2016;40(6):841-846. doi:10.1111/jfd.12536

91. Easwaran DA, El-Didamony G, Megahed M. New approach to use phage therapy against *Aeromonas hydrophila* induced motile *Aeromonas* septicemia in Nile tilapia. *J Marine Sci Res Dev*. 2016;6(3):2. doi:10.4172/2155-9910.1000194
92. Hassan SWM, Ali SM, AlMisherfi MM. Isolation and molecular characterization of some marine *Aeromonas* phages: Protective effects for Nile tilapia infected with *Aeromonas hydrophila*. *J Pure Appl Microbiol*. 2018;12(3):1175-1185. doi:10.22207/jpam.12.3.17
93. Le TS, Nguyen TH, Vo HP, et al. Protective effects of bacteriophages against *Aeromonas hydrophila* causing motile *Aeromonas* septicemia (MAS) in striped catfish. *Antibiotics*. 2018;7(1):16. doi:10.3390/antibiotics7010016
94. Hoang AH, Pham DTM. Phage Cocktails to Inactivate *Edwardsiella ictaluri*, an infectious agent in striped catfish *Pangasianodon hypophthalmus*. *Chemical Engineering Transactions*. 2021;89:535-540. doi:10.3303/CET2189090
95. Tu HA, Xuan TT, Le P, Dang DTH. Selection of phages to control *Aeromonas hydrophila* an infectious agent in striped catfish. *Biocontrol Sci*. 2019;24(1):23-28. doi:10.4265/bio.24.23
96. Tu VQ, Nguyen TT, Tran XTT, et al. Complete genome sequence of a novel lytic phage infecting *Aeromonas hydrophila*, an infectious agent in striped catfish (*Pangasianodon hypophthalmus*). *Arch Virol*. 2020;165(12):2973-2977. doi:10.1007/s00705-020-04793-2
97. Akmal M, Rahimi-Midani A, Hafeez-ur-Rehman M, Hussain A, Choi TJ. Isolation, characterization, and application of a bacteriophage infecting the fish pathogen *Aeromonas hydrophila*. *Pathogens*. 2020;9(3):215. doi:10.3390/pathogens9030215
98. Cao Y, Li S, Han S, et al. Characterization and application of a novel *Aeromonas* bacteriophage as treatment for pathogenic *Aeromonas hydrophila* infection in rainbow trout. *Aquaculture*. 2020;523:735193. doi:10.1016/j.aquaculture.2020.735193
99. Dien LT, Ky LB, Huy BT, et al. Characterization and protective effects of lytic bacteriophage pAh6.2TG against a pathogenic multidrug-resistant *Aeromonas hydrophila* in Nile tilapia (*Oreochromis niloticus*). *Transboundary Emerging Diseases*. 2021;69(4):435-450. doi:10.1111/tbed.14321
100. Dang THO, Xuan TTT, Duyen LTM, Le NP, Hoang HA. Protective efficacy of phage PVN02 against haemorrhagic septicemia in striped catfish *Pangasianodon hypophthalmus* via oral administration. *J Fish Dis*. 2021;44(8):1255-1263. doi:10.1111/jfd.13387
101. Duarte J, Pereira C, Costa P, Almeida A. Bacteriophages with potential to inactivate *Aeromonas hydrophila* in cockles: In vitro and in vivo preliminary studies. *Antibiotics*. 2021;10(6):710. doi:10.3390/antibiotics10060710
102. Yu H, Feng C, Raza SHA, et al. Characterization and genome analysis of two new *Aeromonas hydrophila* phages, PZL-Ah1 and PZL-Ah8. *Arch Virol*. 2022;167(2):669-673. doi:10.1007/s00705-021-05345-y
103. Pan L, Li D, Lin W, et al. Novel *Aeromonas* phage ahy-yong1 and its protective effects against *Aeromonas hydrophila* in Brocade Carp (*Cyprinus* aka Koi). *Viruses*. 2022;14(11):2498. doi:10.3390/v14112498
104. Schulz P, Pajdak-Czaus J, Robak S, Dastyh J, Siwicki AK. Bacteriophage-based cocktail modulates selected immunological parameters and post-challenge survival of rainbow trout (*Oncorhynchus mykiss*). *J Fish Dis*. 2019;42(8):1151-1160. doi:10.1111/jfd.13026
105. Hsu C, Lo C, Liu J, Lin C. Control of the eel (*Anguilla japonica*) pathogens, *Aeromonas hydrophila* and *Edwardsiella tarda* by bacteriophages. *Journal of Fish Society Taiwan*. 2000;27(1):21-31.
106. Wu JL, Chao WJ. Isolation and application of a new bacteriophage, ET-1, which infect *Edwardsiella tarda*, the pathogen of edwardsiellosis. *Report Fish Diseases Research (Taiwan)*. 1982;4:8-17.
107. Yamamoto A, Maegawa T. Phage typing of *Edwardsiella tarda* from eel farm and diseased eel. *Aquaculture Science*. 2008;56(4):611-612. doi:10.1123/3/aquaculturesci.56.611
108. Nikapitiya C, Chandrarathna HPSU, Dananjaya SHS, De Zoysa M, Lee J. Isolation and characterization of phage (ETP-1) specific to multidrug resistant pathogenic *Edwardsiella tarda* and its in vivo biocontrol efficacy in zebrafish (*Danio rerio*). *Biologicals*. 2020;63:14-23. doi:10.1016/j.biologics.2019.12.006
109. Cui H, Xu Y, Cong C, et al. Evaluation of the preventive effect of phage cocktails on turbot ascites and its influence on main physiological indicators. *Aquaculture*. 2022;547:737539. doi:10.1016/j.aquaculture.2021.737539

110. Matsuoka S, Nakai T. Seasonal appearance of *Edwardsiella tarda* and its bacteriophages in the culture farms of Japanese flounder. *Fish Pathol.* 2004;39(3):145-152. doi:10.3147/jsfp.39.145
111. Walakira JK, Carrias AA, Hossain MJ, Jones E, Terhune JS, Liles MR. Identification and characterization of bacteriophages specific to the catfish pathogen, *Edwardsiella ictaluri*. *Journal of Applied Microbiology.* 2008;105(6):2133-2142. doi:10.1111/j.1365-2672.2008.03933.x
112. Carrias A, Welch TJ, Waldbieser GC, Mead DA, Terhune JS, Liles MR. Comparative genomic analysis of bacteriophages specific to the channel catfish pathogen *Edwardsiella ictaluri*. *Virol J.* 2011;8(1):1-12. doi:10.1186/1743-422x-8-6
113. Xu Z, Shao S, Ding Z, et al. Therapeutic efficacies of two newly isolated edwardsiella phages against *Edwardsiella piscicida* Infection. *Microbiological Research.* 2022;263:127043. doi:10.1016/j.micres.2022.127043
114. Chen L, Fan J, Yan T, et al. Isolation and characterization of specific phages to prepare a cocktail preventing *Vibrio* sp. va-f3 infections in shrimp (*Litopenaeus vannamei*). *Front Microbiol.* 2019;10:2337. doi:10.3389/fmicb.2019.02337
115. Karunasagar I, Shivu MM, Girisha SK, Krohne G, Karunasagar I. Biocontrol of pathogens in shrimp hatcheries using bacteriophages. *Aquaculture.* 2007;268(1-4):288-292. doi:10.1016/j.aquaculture.2007.04.049
116. Shivu MM, Rajeeva BC, Girisha SK, Karunasagar I, Krohne G, Karunasagar I. Molecular characterization of *Vibrio harveyi* bacteriophages isolated from aquaculture environments along the coast of India. *Environ Microbiol.* 2007;9(2):322-331. doi:10.1111/j.1462-2920.2006.01140.x
117. Vinod MG, Shivu MM, Umesha KR, et al. Isolation of *Vibrio harveyi* bacteriophage with a potential for biocontrol of luminous vibriosis in hatchery environments. *Aquaculture.* 2006;255(1-4):117-124. doi:10.1016/j.aquaculture.2005.12.003
118. Srinivasan P, Ramasamy P, Brennan GP, Hanna REB. Inhibitory effects of bacteriophages on the growth of *Vibrio* sp., pathogens of shrimp in the Indian aquaculture environment. *Asian J of Animal Veterinary Advances.* 2007;2(4):166-183. doi:10.3923/ajava.2007.166.183
119. Stalin N, Srinivasan P. Efficacy of potential phage cocktails against *Vibrio harveyi* and closely related *Vibrio* species isolated from shrimp aquaculture environment in the south east coast of India. *Veterinary Microbiology.* 2017;207:83-96. doi:10.1016/j.vetmic.2017.06.006
120. Crothers-Stomps C, Høj L, Bourne DG, Hall MR, Owens L. Isolation of lytic bacteriophage against *Vibrio harveyi*. *Journal of Applied Microbiology.* 2010;108(5):1744-1750. doi:10.1111/j.1365-2672.2009.04578.x
121. Cui H, Cong C, Wang L, et al. Protective effectiveness of feeding phage cocktails in controlling *Vibrio harveyi* infection of turbot *Scophthalmus maximus*. *Aquaculture.* 2021;535:736390. doi:10.1016/j.aquaculture.2021.736390
122. Phumkhachorn P, Rattanachaikunsopon P. Isolation and partial characterization of a bacteriophage infecting the shrimp pathogen *Vibrio harveyi*. *African Journal of Microbiology Research.* 2010;4(16):1794-1800.
123. Oakey HJ, Owens L. A new bacteriophage, VHML, isolated from a toxin-producing strain of *Vibrio harveyi* in tropical Australia. *J Appl Microbiol.* 2000;89(4):702-709. doi:10.1046/j.1365-2672.2000.01169.x
124. Wang Y, Barton M, Elliott L, et al. Bacteriophage therapy for the control of *Vibrio harveyi* in greenlip abalone (*Haliotis laevis*). *Aquaculture.* 2017;473:251-258. doi:10.1016/j.aquaculture.2017.01.003
125. Jun JW, Kim HJ, Yun SK, Chai JY, Park SC. Eating oysters without risk of vibriosis: Application of a bacteriophage against *Vibrio parahaemolyticus* in oysters. *International Journal of Food Microbiology.* 2014;188:31-35. doi:10.1016/j.ijfoodmicro.2014.07.007
126. Jun JW, Han JE, Giri SS, et al. Phage application for the protection from acute hepatopancreatic necrosis disease (AHPND) in *Penaeus vannamei*. *Indian J Microbiol.* 2017;58(1):114-117. doi:10.1007/s12088-017-0694-9
127. Yang M, Liang Y, Huang S, et al. Isolation and characterization of the novel phages vB\_VpS\_BA3 and vB\_VpS\_CA8 for lysing *Vibrio parahaemolyticus*. *Frontier Microbiology.* 2020;11:259. doi:10.3389/fmicb.2020.0025
128. Lomelí-Ortega CO, Martínez-Díaz SF. Phage therapy against *Vibrio parahaemolyticus* infection in the whiteleg shrimp (*Litopenaeus vannamei*) larvae. *Aquaculture.* 2014;434:208-211. doi:10.1016/j.aquaculture.2014.08.018

129. Matamp N, Bhat SG. Genome characterization of novel lytic Myoviridae bacteriophage  $\phi$ VP-1 enhances its applicability against MDR-biofilm-forming *Vibrio parahaemolyticus*. *Arch Virol*. 2019;165(2):387-396. doi:10.1007/s00705-019-04493-6
130. Rong R, Lin H, Wang J, Khan MN, Li M. Reductions of *Vibrio parahaemolyticus* in oysters after bacteriophage application during depuration. *Aquaculture*. 2014;418:171-176. doi:10.1016/j.aquaculture.2013.09.028
131. Mateus L, Costa L, Silva YJ, Pereira C, Cunha A, Almeida A. Efficiency of phage cocktails in the inactivation of *Vibrio* in aquaculture. *Aquaculture*. 2014;424-425:167-173. doi:10.1016/j.aquaculture.2014.01.001
132. Bastías R, Higuera G, Sierralta W, Espejo RT. A new group of cosmopolitan bacteriophages induce a carrier state in the pandemic strain of *Vibrio parahaemolyticus*. *Environmental Microbiology*. 2010;12(4):990-1000. doi:10.1111/j.1462-2920.2010.02143.x
133. Dubey S, Singh A, Kumar BTN, Singh NK, Tyagi A. Isolation and characterization of bacteriophages from inland saline aquaculture environments to control *Vibrio parahaemolyticus* contamination in shrimp. *Indian J Microbiol*. 2021;61(2):212-217. doi:10.1007/s12088-021-00934-6
134. Alagappan K, Karuppiah V, Deivasigamani B. Protective effect of phages on experimental *V. parahaemolyticus* infection and immune response in shrimp (Fabricius, 1798). *Aquaculture*. 2016;453:86-92. doi:10.1016/j.aquaculture.2015.11.037
135. Ren H, Li Z, Xu Y, Wang L, Li X. Protective effectiveness of feeding phage cocktails in controlling *Vibrio parahaemolyticus* infection of sea cucumber *Apostichopus japonicus*. *Aquaculture*. 2019;503:322-329. doi:10.1016/j.aquaculture.2019.01.006
136. Higuera G, Bastías R, Tsertsvadze G, Romero J, Espejo RT. Recently discovered *Vibrio anguillarum* phages can protect against experimentally induced vibriosis in Atlantic salmon, *Salmo salar*. *Aquaculture*. 2013;392-395:128-133. doi:10.1016/j.aquaculture.2013.02.013
137. Cagatay IT. Bacteriophages to control marine fish pathogens. In: *First EMBO Conference on Aquatic Microbial Ecology*. SAME13; 2013.
138. Rørbo N, Rønneseth A, Kalatzis P, et al. Exploring the effect of phage therapy in preventing *Vibrio anguillarum* infections in cod and turbot larvae. *Antibiotics*. 2018;7(2):42. doi:10.3390/antibiotics7020042
139. Silva YJ, Costa L, Pereira C, et al. Phage therapy as an approach to prevent *Vibrio anguillarum* infections in fish larvae production. *PLoS ONE*. 2014;9(12):e114197. doi:10.1371/journal.pone.0114197
140. Kalatzis PG, Bastías R, Kokkari C, Katharios P. Isolation and characterization of two lytic bacteriophages,  $\phi$ St2 and  $\phi$ Grn1; phage therapy application for biological control of *Vibrio alginolyticus* in aquaculture live feeds. *PLoS ONE*. 2016;11(3):e0151101. doi:10.1371/journal.pone.0151101
141. Kokkari C, Sarropoulou E, Bastias R, Mandalakis M, Katharios P. Isolation and characterization of a novel bacteriophage infecting *Vibrio alginolyticus*. *Arch Microbiol*. 2018;200(5):707-718. doi:10.1007/s00203-018-1480-8
142. Cohen Y, Joseph Pollock F, Rosenberg E, Bourne DG. Phage therapy treatment of the coral pathogen *Vibrio coralliilyticus*. *Microbiology Open*. 2012;2(1):64-74. doi:10.1002/mbo3.52
143. Kim HJ, Jun JW, Giri SS, et al. Application of the bacteriophage pVco-14 to prevent *Vibrio coralliilyticus* infection in Pacific oyster (*Crassostrea gigas*) larvae. *Journal of Invertebrate Pathology*. 2019;167:107244. doi:10.1016/j.jip.2019.107244
144. Kim HJ, Giri SS, Kim SG, et al. Isolation and characterization of two bacteriophages and their preventive effects against pathogenic *Vibrio coralliilyticus* causing mortality of Pacific oyster (*Crassostrea gigas*) larvae. *Microorganisms*. 2020;8(6):926. doi:10.3390/microorganisms8060926
145. Katharios P, Kalatzis PG, Kokkari C, Sarropoulou E, Middelboe M. Isolation and characterization of a N4-like lytic bacteriophage infecting *Vibrio splendidus*, a pathogen of fish and bivalves. *PLoS ONE*. 2017;12(12):e0190083. doi:10.1371/journal.pone.0190083
146. Veyrand-Quirós B, Gómez-Gil B, Lomeli-Ortega CO, et al. Use of bacteriophage vB\_Pd\_PDCC-1 as biological control agent of *Photobacterium damsela* subsp. *damsela* during hatching of longfin yellowtail (*Seriola rivoliana*) eggs. *J Appl Microbiol*. 2020;129(6):1497-1510. doi:10.1111/jam.14744

147. Kawato Y, Yasuike M, Nakamura Y, et al. Complete genome sequence analysis of two *Pseudomonas plecoglossicida* phages, potential therapeutic agents. *Appl Environ Microbiol*. 2015;81(3):874-881. [doi:10.1128/aem.03038-14](https://doi.org/10.1128/aem.03038-14)
148. Khairnar K, Raut MP, Chandekar RH, Sanmukh SG, Paunikar WN. Novel bacteriophage therapy for controlling metallo-beta-lactamase producing *Pseudomonas aeruginosa* infection in Catfish. *BMC Vet Res*. 2013;9(1):264. [doi:10.1186/1746-6148-9-264](https://doi.org/10.1186/1746-6148-9-264)
149. Hoai TD, Yoshida T. Induction and characterization of a lysogenic bacteriophage of *Lactococcus garvieae* isolated from marine fish species. *J Fish Dis*. 2015;39(7):799-808. [doi:10.1111/jfd.12410](https://doi.org/10.1111/jfd.12410)
150. Nakai T, Sugimoto R, Park K, et al. Protective effects of bacteriophage on experimental *Lactococcus garvieae* infection in yellowtail. *Dis Aquat Org*. 1999;37:33-41. [doi:10.3354/dao037033](https://doi.org/10.3354/dao037033)
151. Park K, Matsuoka S, Nakai T, Muroga K. A virulent bacteriophage of *Lactococcus garvieae* (formerly *Enterococcus seriolicida*) isolated from yellowtail *Seriola quinqueradiata*. *Dis Aquat Org*. 1997;29(2):145-149. [doi:10.3354/dao029145](https://doi.org/10.3354/dao029145)
152. Park SC, Shimamura I, Fukunaga M, Mori KI, Nakai T. Isolation of bacteriophages specific to a fish pathogen, *Pseudomonas plecoglossicida*, as a candidate for disease control. *Appl Environ Microbiol*. 2000;66(4):1416-1422. [doi:10.1128/aem.66.4.1416-1422.2000](https://doi.org/10.1128/aem.66.4.1416-1422.2000)
153. Hoai TD, Nishiki I, Fujiwara A, Yoshida T, Nakai T. Comparative genomic analysis of three lytic *Lactococcus garvieae* phages, novel phages with genome architecture linking the 936 phage species of *Lactococcus lactis*. *Marine Genomics*. 2019;48:100696. [doi:10.1016/j.margen.2019.100696](https://doi.org/10.1016/j.margen.2019.100696)
154. Akmal M, Nishiki I, Zrelavs N, Yoshida T. Complete genome sequence of a novel lytic bacteriophage, PLG-II, specific for *Lactococcus garvieae* serotype II strains that are pathogenic to fish. *Arch Virol*. 2022;167(11):2331-2335. [doi:10.1007/s00705-022-05568-7](https://doi.org/10.1007/s00705-022-05568-7)
155. Ghasemi SM, Bouzari M, Emtiazi G. Preliminary characterization of *Lactococcus garvieae* bacteriophage isolated from wastewater as a potential agent for biological control of lactococcosis in aquaculture. *Aquacult Int*. 2014;22(4):1469-1480. [doi:10.1007/s10499-014-9760-z](https://doi.org/10.1007/s10499-014-9760-z)
156. Matsuoka S, Hashizume T, Kanzaki H, et al. Phage therapy against  $\beta$ -hemolytic streptococcosis of Japanese flounder *Paralichthys olivaceus*. *Fish Pathol*. 2007;42(4):181-189. [doi:10.3147/jsfp.42.181](https://doi.org/10.3147/jsfp.42.181)
157. Strand A. *Analyses of Bacteriophages to Yersinia Ruckeri and the Salmon (Salmo Salar L.) Antibody Response to the Bacteriophages*. Master's thesis. The University of Bergen; 2017.
158. Leskinen K, Pajunen MI, Vilanova MVGR, et al. YerA41, a *Yersinia ruckeri* bacteriophage: determination of a non-sequencable DNA bacteriophage genome via RNA-Sequencing. *Viruses*. 2020;12(6):620. [doi:10.3390/v12060620](https://doi.org/10.3390/v12060620)
159. Welch TJ. Characterization of a novel *Yersinia ruckeri* serotype O1-specific bacteriophage with virulence-neutralizing activity. *J Fish Dis*. 2019;43(2):285-293. [doi:10.1111/jfd.13124](https://doi.org/10.1111/jfd.13124)
160. Prasad Y, Kumar AD. Isolation and efficacy evaluation of virulent bacteriophages specific to fish pathogenic bacterium, *Flavobacterium columnare*. *Journal of Applied Animal Research*. 2010;38(2):169-174. [doi:10.1080/09712119.2010.10539505](https://doi.org/10.1080/09712119.2010.10539505)
161. Prasad Y, Kumar D, Sharma AK. Lytic bacteriophages specific to *Flavobacterium columnare* rescue catfish, *Clarias batrachus* (Linn.) from columnaris disease. *Journal Environmental Biology*. 2011;32(2):161-168.
162. Laanto E, Sundberg LR, Bamford JKH. Phage specificity of the freshwater fish pathogen *Flavobacterium columnare*. *Appl Environ Microbiol*. 2011;77(21):7868-7872. [doi:10.1128/aem.05574-11](https://doi.org/10.1128/aem.05574-11)
163. Laanto E, Bamford JKH, Ravantti JJ, Sundberg LR. The use of phage FCL-2 as an alternative to chemotherapy against columnaris disease in aquaculture. *Front Microbiol*. 2015;6:829. [doi:10.3389/fmicb.2015.00829](https://doi.org/10.3389/fmicb.2015.00829)
164. Kunttu HMT, Runtuvuori-Salmela A, Sundell K, et al. Bacteriophage resistance affects *Flavobacterium columnare* virulence partly via mutations in genes related to gliding motility and the Type IX secretion system. *Appl Environ Microbiol*. 2021;87(16):00812-00821. [doi:10.1128/aem.00812-21](https://doi.org/10.1128/aem.00812-21)
165. Cagatay IT. Use of bacteriophages against fish pathogens. 17. *National Aquaculture symposium Istanbul*. Published online 2013.
166. Runtuvuori-Salmela A, Kunttu HMT, Laanto E, et al. Prevalence of genetically similar *Flavobacterium columnare* phages across aquaculture environments reveals a strong potential for pathogen control. *Environmental Microbiology*. 2022;24(5):2404-2420. [doi:10.1111/1462-2920.15901](https://doi.org/10.1111/1462-2920.15901)

167. Stenholm AR, Dalsgaard I, Middelboe M. Isolation and characterization of bacteriophages infecting the fish pathogen *Flavobacterium psychrophilum*. *Appl Environ Microbiol*. 2008;74(13):4070-4078. doi:10.1128/aem.00428-08
168. Kim JH, Gomez DK, Nakai T, Park SC. Isolation and identification of bacteriophages infecting ayu *Plecoglossus altivelis altivelis* specific *Flavobacterium psychrophilum*. *Veterinary Microbiology*. 2010;140(1-2):109-115. doi:10.1016/j.vetmic.2009.07.002
169. Castillo D, Higuera G, Villa M, et al. Diversity of *Flavobacterium psychrophilum* and the potential use of its phages for protection against bacterial cold water disease in salmonids. *Journal of Fish Diseases*. 2012;35(3):193-201. doi:10.1111/j.1365-2761.2011.01336.x
170. Madsen L, Bertelsen SK, Dalsgaard I, Middelboe M. Dispersal and survival of *Flavobacterium psychrophilum* phages *in vivo* in rainbow trout and *in vitro* under laboratory conditions: implications for their use in phage therapy. *Appl Environ Microbiol*. 2013;79(16):4853-4861. doi:10.1128/aem.00509-13
171. Christiansen RH, Dalsgaard I, Middelboe M, Lauritsen AH, Madsen L. Detection and quantification of *Flavobacterium psychrophilum*-specific bacteriophages *in vivo* in rainbow trout upon oral administration: implications for disease control in aquaculture. *Appl Environ Microbiol*. 2014;80(24):7683-7693. doi:10.1128/aem.02386-14
172. Donati VL, Dalsgaard I, Runtuvuori-Salmela A, et al. Interactions between rainbow trout eyed eggs and *Flavobacterium* spp. using a bath challenge model: preliminary evaluation of bacteriophages as pathogen control agents. *Microbiology*. 2021;9(5):971. doi:10.3390/microorganisms9050971
173. Donati VL, Dalsgaard I, Sundell K, et al. Phage-mediated control of *Flavobacterium psychrophilum* in aquaculture: In vivo experiments to compare delivery methods. *Frontier Microbiology*. 2021;12:628309. doi:10.3389/fmicb.2021.628309
174. Le ST, Kurtböke İ. Bacteriophages as biocontrol agents in aquaculture. *Microbiol Aust*. 2019;40(1):37. doi:10.1071/ma19003
175. Huang K, Nitin N. Edible bacteriophage based antimicrobial coating on fish feed for enhanced treatment of bacterial infections in aquaculture industry. *Aquaculture*. 2019;502:18-25. doi:10.1016/j.aquaculture.2018.12.026
176. Wan-Mohtar WAAQI, Ibrahim MF, Rasdi NW, Zainorahim N, Taufek NM. Microorganisms as a sustainable aquafeed ingredient: A review. *Aquaculture Research*. 2022;53(3):746-766. doi:10.1111/are.15627
177. Monk AB, Rees CD, Barrow P, Hagens S, Harper DR. Bacteriophage applications: where are we now? *Letters in Applied Microbiology*. 2010;51(4):363-369.
178. Phage Biotech. *Developments*. Phage Biotech Ltd; 2017.
179. Intralytix I. Intralytix, Inc. Published 2018. <http://www.intralytix.com/>
180. Grzelak J. BAFADOR®. Presented at: international bacteriophage conference in Tbilisi; 2017.
181. Wojtasik A, Gorecka E, Wojcik E, et al. Bacteriophage strains and their applications. *Patent*. Published online 2017.
182. ACD Pharma. *Bacteriophage Therapy*. ACD Pharma; 2021.
183. Matthey M. Treatment of Bacterial Infections in Aquaculture. *US Patent*. 2016;10:849-942.
184. Mangalore Biotech Laboratory. Mangalore biotech lab. Products. Published 2019. <http://mangalorebiotech.com/products.html>
185. El Araby D, El-Didamony G. New approach to use phage therapy against *Aeromonas hydrophila* induced motile *Aeromonas* septicemia in Nile tilapia. *J Marine Sci Res Dev*. 2016;6(3):2. doi:10.4172/2155-9910.1000194
186. Pereira C, Duarte J, Costa P, Braz M, Almeida A. Bacteriophages in the control of *Aeromonas* sp. in aquaculture systems: an integrative view. *Antibiotics*. 2022;11(2):163. doi:10.3390/antibiotics11020163
187. Letchumanan V, Chan KG, Pusparajah P, et al. Insights into bacteriophage application in controlling *Vibrio* species. *Front Microbiol*. 2016;7:1114. doi:10.3389/fmicb.2016.01114